Related Experiment Video
Updated: Jul 10, 2026
A Pre-Clinical Porcine Model of Orthotopic Heart Transplantation
Published on: April 27, 2019
Ventricular Volumetric Changes After Transcatheter Tricuspid Valve Replacement in a Heart Transplant Recipient
Denizhan Ozdemir1, Mandeep Singh1, Farhan A Bajwa1
1University of Rochester Medical Center, Rochester, New York, USA.
Background:
Severe tricuspid regurgitation is a common complication after orthotopic heart transplantation (OHT), but transplant recipients are underrepresented in transcatheter trials. Early ventricular volume and ejection fraction changes after transcatheter tricuspid valve replacement (TTVR) in this population remain unclear.
Case Summary:
A 62-year-old man with nonischemic cardiomyopathy, and subsequent OHT developed NYHA functional class III symptoms from severe tricuspid regurgitation. Transcatheter edge-to-edge repair was deemed unfeasible because of imaging limitations. Computed tomography demonstrated annular dilation, and TTVR with a 44-mm EVOQUE valve was performed. At 30 days, the valve was well functioning, without significant residual regurgitation or hypoattenuated leaflet thickening. Repeat computed tomography showed reduced biventricular end-diastolic volumes, with increased left ventricular and effective right ventricular ejection fractions.
Discussion:
This case supports feasibility and early physiologic directional ventricular changes after EVOQUE implantation in an OHT patient.
Take-Home Message:
TTVR is safe in OHT recipients, with early favorable changes in biventricular volumes and function.
